ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
复制标题
ChAdOx1 nCoV-19 疫苗:无症状疗效估计。
DOI:
10.1016/s0140-6736(21)00951-x
复制
发表时间:
2021
期刊:
影响因子:
--
通讯作者:
Platts-Mills,JamesA
中科院分区:
文献类型:
--
作者:
McQuade,ElizabethTRogawski;Platts-Mills,JamesA
Yemen has one of the most fragile health-care systems and is currently experiencing war and famine. Since 2015, the country’s humanitarian crisis has resulted in the emergence and reemergence of debilitating infectious diseases and severely weakened the country’s health infrastructure. The first COVID-19 case in Yemen was reported in April, 2020, and WHO warned of a possible catastrophic explosion of cases. 1 Early epidemiological data showed a high mortality rate in individuals younger than 60 years. 2 In the absence of well equipped laboratories, infrastructure, and testing tools, misdiagnoses and underestimation of new cases have resulted in inconsistencies in reported case numbers. Indeed, a recent geospatial analysis of burial activity in the Aden governorate3 during the pandemic suggested a substantial, under-ascertained impact of COVID-19, implying that reported mortality data are inaccurate.According to the latest WHO Yemen Situation Report for March, 2021, 4 Yemen has received 360 000 doses of AstraZeneca COVID-19 vaccines through the COVAX initiative. Yemen is expecting to receive 14 million doses of COVID-19 vaccines through the COVAX, enough to vaccinate about 23% of the population. 5 According to OurWorldInData COVID-19 vaccinations dashboard, as of May 29, 2021, just over 104 000 people have received at least one dose of COVID-19 vaccine. All things considered, it is important to fashion out a safe model for vaccination rollout in Yemen, a country without a system for tracking virus spread in its susceptible community. Worthy of note is the fact that just less than 3% of the Yemeni population is older than 65 years, which is relatively small proportion of the population compared with many other